Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Income from Continuing Operations (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Income from Continuing Operations for 7 consecutive years, with 39057000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 32.13% to 39057000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 191101000.0 through Dec 2025, up 24.53% year-over-year, with the annual reading at 190886000.0 for FY2025, 25.9% up from the prior year.
  • Income from Continuing Operations hit 39057000.0 in Q4 2025 for Allogene Therapeutics, up from 41319000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 1893000.0 in Q4 2021 to a low of 97033000.0 in Q1 2023.
  • Historically, Income from Continuing Operations has averaged 63185900.0 across 5 years, with a median of 65806000.0 in 2024.
  • Biggest five-year swings in Income from Continuing Operations: skyrocketed 102.76% in 2021 and later crashed 5046.54% in 2022.
  • Year by year, Income from Continuing Operations stood at 1893000.0 in 2021, then plummeted by 5046.54% to 93638000.0 in 2022, then grew by 15.8% to 78844000.0 in 2023, then increased by 27.02% to 57544000.0 in 2024, then skyrocketed by 32.13% to 39057000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for ALLO at 39057000.0 in Q4 2025, 41319000.0 in Q3 2025, and 50900000.0 in Q2 2025.